Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590. doi:10.1097/CM9.0000000000002108
   PubMed Web of Science ®Google Scholar
• Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American society of clinical oncology endorsement of the American college of chest physicians guideline. J Clin Oncol. 2015;33(34):4106–4111. doi:10.1200/JCO.2015.63.7918
   PubMed Web of Science ®Google Scholar
• van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741–1755. doi:10.1016/S0140-6736(11)60165-7
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619–630. doi:10.1200/JCO.20.01055
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, Phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65. doi:10.1016/S1470-2045(20)30539-8
   PubMed Web of Science ®Google Scholar
• Guidelines Working Committee of Chinese society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology (CSCO) for Small Cell Lung Cancer. Beijing: People’s Medical Publishing House; 2021:141.
   Google Scholar
• Li LY, Wang H, Chen X, et al. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin Med J. 2019;132(23):2790–2794. doi:10.1097/CM9.0000000000000536
   PubMed Web of Science ®Google Scholar
• Liu G, Kang S. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert Rev Pharmacoecon Outcomes Res. 2022;22(1):85–91. doi:10.1080/14737167.2021.1888717
   PubMed Web of Science ®Google Scholar
• Central People’s Government of the People’s Republic of China. China has strengthened the research and development of anti-cancer drugs and promoted the supply guarantee of patented drugs. Available from: http://www.gov.cn/xinwen/2018-08/06/content_5311957.htm.Accessed January 11, 2021.
   Google Scholar
• Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739–747. doi:10.1016/S1470-2045(22)00224-8
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhou Z, Luo X, et al. First-Line ICI monotherapies for advanced non-small-cell lung cancer patients With PD-L1 of at least 50%: a cost-effectiveness analysis. Front Pharmacol. 2021;12:788569. doi:10.3389/fphar.2021.788569
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Ollendorf DA. Drug-pricing debate redux - should cost-effectiveness analysis be used now to price pharmaceuticals? N Engl J Med. 2021;385(21):1923–1924. doi:10.1056/NEJMp2113323
   PubMed Web of Science ®Google Scholar
• Hammad EA. The use of economic evidence to inform drug pricing decisions in Jordan. Value Health. 2016;19(2):233–238. doi:10.1016/j.jval.2015.11.007
   PubMed Web of Science ®Google Scholar
• Chinese Pharmaceutical Association. China guidelines for pharmacoeconomic evaluations; 2020. Available from: https://www.cpa.org.cn/cpadmn/attached/file/20201203/1606977380634185.pdf. Accessed April 22, 2021.
   Google Scholar
• Shen Y, Wu B, Wang X, et al. Health state utilities in patients with advanced non-small-cell lung cancer in China. J Comp Eff Res. 2018;7(5):443–452. doi:10.2217/cer-2017-0069
   PubMed Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195–e203. doi:10.1111/ajco.12477
   PubMed Web of Science ®Google Scholar
• National Bureau Of Statistics. National annual data. Available from: https://data.stats.gov.cn/easyquery.htm?cn=C01. Accessed January 1, 2022.
   Google Scholar
• National Health Industry Data Platform. Bid winning information of drugs. Available from: https://www.yaozh.com/. Accessed 15, July 2021.
   Google Scholar
• Luo X, Liu Q, Zhou Z, et al. Cost-effectiveness of bevacizumab biosimilar ly01008 combined with chemotherapy as first-line treatment for Chinese patients with advanced or recurrent nonsquamous non-small cell lung cancer. Front Pharmacol. 2022;13:832215. doi:10.3389/fphar.2022.832215
   PubMed Web of Science ®Google Scholar
• U.S. FDA National Drug Code DataBase. IMFINZI® (durvalumab) injection, for intravenous use. Available from: https://www.drugfuture.com/fda-ndc/label.aspx?ProductNDC=0310-4500. Accessed 16, September 2021.
   Google Scholar
• Li G, Qin Y, Xie C, et al. Trends in oncology drug innovation in China. Nat Rev Drug Discov. 2021;20(1):15–16. doi:10.1038/d41573-020-00195-w
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Press conference of the information office of the state council on December 23, 2020. Available from: http://www.nhc.gov.cn/xcs/s3574/202012/bc4379ddf4324e7f86f05d31cc1c4982.shtml. Accessed January 28, 2022.
   Google Scholar
• National Health Commission of the People’s Republic of China. Notice on printing and distributing major science and technology projects of “major new drug creation”. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=37578. Accessed February 28, 2021.
   Google Scholar
• National Health Industry Data Platform. Domestic drugs. https://db.yaozh.com/pijian. Accessed 15, July 2021.
   Google Scholar
• Yip W, Fu H, Chen AT, et al. 10 years of health-care reform in China: progress and gaps in universal health coverage. Lancet. 2019;394(10204):1192–1204. doi:10.1016/S0140-6736(19)32136-1
   PubMed Web of Science ®Google Scholar
• National Healthcare security Administration. Statistical bulletin on the development of national medical security in 2020. Available from: http://www.nhsa.gov.cn/art/2021/6/8/art_7_5232.html. Accessed 15, August 2021.
   Google Scholar